Garmin Ltd. vs Illumina, Inc. — how do they compare? Garmin Ltd. trades at $309.51 (market cap $60.39B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Garmin Ltd. is far larger — about 2.1× Illumina, Inc.'s market cap, and Garmin Ltd. pays a 1.34% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| GRMN | ILMN | |
|---|---|---|
Market Cap | $60.39B | $28.96B |
Sector | Technology | Health |
52-Week High | $313.16 | $205.10 |
52-Week Low | $187.10 | $91.00 |
Enterprise Value | $57.91B | $30.32B |
Dividend Yield | 1.34% | — |
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $310.89, up 2.96% today and near its all-time high, with a bullish technical trend supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.81 versus $2.30 expected, and raised full-year guidance. Revenue growth is robust, driven by the fitness segment, with 2025 revenue at $7.25 billion and net income margin of 24.47%.
Outlook is positive due to sustained demand for wearables and upward revisions, but risks include rich valuations (P/E of 32.08) and potential growth deceleration. Analyst consensus is cautious with 74% hold ratings, though the price target of $318.67 suggests modest upside. Investors should weigh strong fundamentals against high expectations.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Trailing returns across standard periods
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →